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Abstract: The female inflorescences of hops (Humulus lupulus L.), a well-known bittering 
agent used in the brewing industry, have long been used in traditional medicines. Xanthohumol 
(XN) is one of the bioactive substances contributing to its medical applications. Among 
foodstuffs XN is found primarily in beer and its natural occurrence is surveyed. In recent 
years, XN has received much attention for its biological effects. The present review describes 
the pharmacological aspects of XN and summarizes the most interesting findings obtained 
in the preclinical research related to this compound, including the pharmacological activity, 
the pharmacokinetics, and the safety of XN. Furthermore, the potential use of XN as a food 
additive considering its many positive biological effects is discussed. 
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1. Introduction 
Hops (Humulus lupulus L.) flowers (Figure 1A,B) are widely used throughout the world as a raw 
material in the brewing industry, to preserve beer and to give beer its characteristic aroma and flavor. In 
addition to the application in the brewing industry, hops have for a long time been used for various 
medical purposes [1]. Prenylated flavonoids are one kind of bioactive substances contributing to its 
medical applications. The most abundant prenylated flavonoid in hops is xanthohumol (XN, Figure 1C). 
In nature, XN exists ubiquitously within hops plant, with a content of 0.1%–1% (dry weight) in the 
female inflorescences. XN is secreted mainly as part of the hop resin and is also found in the trichomes 
on the underside of young leaves. The conventional XN isolation method was to use repeated 
chromatographic steps on silica gel using different solvents [2], and the recently established efficient 
way for the isolation and purification of XN from hops extract is by means of a high-speed  
counter-current chromatography method [3]. A chemical synthesis method to synthesize XN using 
phloracetophenone (2',4',6'-trihydroxyacetophenone) as precursor has been established. However, the 
process is complicated and the overall yield is relatively low [4]. Thus, extraction, isolation, and 

















Figure 1. Female hop flowers (A); hop flowers resin covering flower bracts (B); and 
structure of xanthohumol, isoxanthohumol, and kuraridine (C).  
Beer is the most important dietary source of XN and related prenylflavonoids. However, XN is 
generally a minor prenylflavonoid in beer due to the thermal isomerization of chalcones into flavanones, 
in this case isoxanthohumol (IX), occurring during the brewing process [5]. In commercial beers, less 
than 0.2 mg·XN/L is found, which is not enough to really be beneficial to the health. In order to increase 
the yield of XN in the brewing process, the parameters of XN recovery were modified, including the use 
of XN-enriched hop products, the use of special malts, the late addition of hops to the boiling worts, and 
control of the temperature for addition of XN products to sweet worts [5–7]. Consequently, brewing 
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technology that produces beer with high XN content has been established on an industrial scale [6,7]. 
The daily intake of XN is relatively small compared to total polyphenols from beer [8], indicating that 
XN contributes little to the antioxidant properties of beer. However, XN is more lipophilic and therefore 
possibly possess more bioactivity than other beer polyphenols [9]. 
The structure of XN was first identified by Verzele in 1957 [10], but only in the last decade, was XN 
rediscovered, focusing in particular on its multiple bioactivities, including anticancer, antidiabetic, 
antibacterial, anti-inflammatory activities, and so on. The pharmacological activity of XN has gained 
much attention in the functional food and pharmaceutical area. In this review, we focus on the 
bioactivities, pharmacokinetics, safety, and potential application of XN in pharmaceutics, since there are 
only a few reviews related to the possible benefit of XN to human beings [11,12]. 
2. Bioactivity, Pharmacokinetics, and Safety of XN 
2.1. Effect on Metabolic Syndrome and Related Disorders 
Metabolic syndrome is a group of risk factors that include hyperglycemia, abdominal fat, disordered 
cholesterol levels, and high blood pressure. Scientifically validated plant-based interventions are a 
practical means of addressing the epidemics of the metabolic syndrome [13]. Experimental research 
revealed that XN can attenuate several factors of the metabolic syndrome as described below. 
2.1.1. Anti-Obesity Activities 
XN has been reported to inhibit adipogenesis or increase cell apoptosis and therefore can be used in 
preventing obesity. In 3T3-L1 cells, both the purified XN and hops extract rich in XN inhibit the 
differentiation of preadipocytes by decreasing the major adipocyte marker proteins such as peroxisome 
proliferator-activated receptor (PPAR) γ, CCAAT enhancer binding proteins (C/EBP) α, and fatty acid 
binding protein (aP2) [14–16]. In addition, XN also induces apoptosis in mature adipocytes through the 
mitochondrial pathway [14,15]. The differention and apoptosis activity of XN on adipocytes are 
enhanced when used combined with guggulsterone and honokiol [17,18]. As well as effecting adipocytes, 
XN also effects the bioenergetics of muscle cells. XN may attenuate the metabolic syndrome, at least in 
part, through mitochondrial uncoupling and stress response induction [19]. Recent research reported that, 
feeding rats high-fat diet enriched with hop extract, XN inhibits the increase of body weight, liver weight, 
and triacylglycerol level in the plasma and the liver. The mechanisms are related to the regulation of the 
hepatic fatty acid metabolism and inhibition of fat absorption in the intestine [20]. It is interesting that 
α-mangostin with a structure akin to XN is shown to inhibit intracellular fatty acid synthase [21]. XN 
exerts preventive function on the increase of body weight induced by overnutrition, however, further 
clinical investigations are needed to confirm this effect, and the molecular mechanisms for this effect 
have yet to be found. 
2.1.2. Hypoglycemic Activities 
Nutritional approaches using phytonutrients for the prevention or treatment of type 2 diabetes mellitus 
(T2DM) are a rapidly emerging trend. XN has been reported to enhance the metabolism of plasma  
glucose [19,22]. A high XN dose (16.9 mg/kg) exerted beneficial effects on body weight and glucose 
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metabolism in obese male rats [22]. This suggests that XN holds promise as a therapeutic agent for 
treating obesity and dysregulation of both glucose metabolism and the metabolic syndrome [19,22]. 
Levels of plasma glucose, plasma, and hepatic triglyceride in KK-Ay mice decreased when fed with XN. 
The XN-fed mice also showed decreased amounts of water intake, lowered weights of white adipose 
tissue, and exhibited increased levels of plasma adiponectin. This investigation indicates that XN boosts 
glucose metabolism and attenuates diabetes in KK-Ay mice. The mechanisms are possibly related to XN 
acting as a ligand of the farnesoid X receptor, which is positively correlated with lipid accumulation, 
and regulates downstream gene expression [23]. Moreover, research showed consumption of XN by 
diabetic animals consistently decreases inflammation and oxidative stress, allowing neovascularization 
control and improving complicated diabetic wound healing [24]. The inhibition of glucose uptake in 
intestinal cells [25], as well as the inhibition against α-glucosidase [26] may also contribute to the 
hypoglycemic activity of XN. XN has a Michael acceptor moiety that can covalently interact with 
proteins. The inhibition against α-glucosidase is possibly attributed to a Michael-type addition of 
cysteine residues to the α,β-unsaturated keto group of XN [26]. Since the Michael reactions are reversible, 
release of XN recovers the enzyme function in a dialysis experiment and thus explains the reversible 
inhibitory mode [26]. In addition, IX (see Figure 1), a spontaneous cyclization product of XN with no 
electrophilic properties and no ability for Michael addition, does not possess an obvious inhibition effect 
against α-glucosidase [27]. On the other hand, kuraridine, which has a skeleton similar to XN and 
contains the α,β-unsaturated keto group, possesses much stronger inhibitory activities against  
α-glucosidase [27]. Therefore, α-glucosidase is one of the possible targets of XN. All of these findings 
strongly indicate that XN has potential benefits in the treatment of obesity and diabetes. 
2.1.3. Anti-Hyperlipidemia Activities 
In the HepG2 cell model, XN inhibits the synthesis of triglyceride (TG) in the microsomal membrane 
and the transfer of the newly synthesized TG to the microsomal lumen [28]. Moreover, XN decreases 
apolipoprotein B (ApoB) secretion in a dose-dependent manner under both basal and lipid-rich 
conditions and this decrease is associated with increased cellular ApoB degradation. These results 
indicate its potential use in the treatment of hypertriglyceridemia [28]. Research also showed that XN is 
a diacylglycerol acyltransferase inhibitor [29–31], which is involved in triglyceride synthesis. 
High density lipoprotein (HDL)-cholesterol levels are correlated with a low risk of atherosclerosis [32]. 
The inhibition of cholesteryl ester transfer protein (CETP), which catalyses cholesterol transfer between 
lipoproteins, leads to an increase in HDL-cholesterol. CETP is expected to be the next anti-atherogenic 
target. XN has been reported to possess potent inhibition against CETP in a mixed non-competitive 
inhibition mode, and the structure-activity-relationship study showed that the chalcone structure and 
prenyl group is necessary for its inhibitory activity [33]. The inhibitory potency of XN against 
endogenous CETP activity was confirmed in vivo. Via CETP inhibition and the apolipoprotein E (ApoE) 
enhancement, XN prevents cholesterol accumulation in atherogenic regions by HDL-cholesterol 
metabolism in CETP-transgenic mice fed with XN ad libitum for 18 weeks [34]. In Western-type  
diet-fed ApoE-deficient (ApoE−/−) mice, XN also ameliorates atherosclerotic plaque formation [35]. The 
mechanisms are related to their positive effect on plasma cholesterol levels, monocyte chemo attractant 
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protein-1 (MCP-1) concentrations, and hepatic lipid metabolism via activation of AMP-activated protein 
kinase (AMPK) [35]. 
Oxidation of low-density lipoprotein (LDL) is thought to play a central role in atherosclerosis [36]. 
Being a chalcone, XN also possesses superoxide scavenging capacity [37]. XN shows high antioxidant 
activity in inhibiting LDL oxidation. When combined with α-tocopherol, XN completely inhibits  
copper-mediated LDL oxidation. According to these findings, XN protects human LDL from  
oxidation [38]. XN modulates the lipid metabolism and therefore prevents cardiovascular diseases such 
as atherosclerosis. Besides its direct antioxidant activity, XN also induces cellular defense mechanisms 
to overcome the oxidation stress induced by chemicals [39] or surgery [40]. 
2.2. Cancer Related Bioactivities 
Cancer is an abnormal and uncontrollable multiplication of cells or tissue. Agents that inhibit the 
initiation, promotion, and progression stages of carcinogenesis, consist of a broad spectrum of  
chemo-preventive candidates for cancer treatment. In recent years, experimental results of a number of 
studies have showed that XN can prevent and treat cancers [41]. The mechanisms of anticancer activity 
have been identified, including chemopreventive activity by inhibition of the initiation and development 
of carcinogenesis, and therapeutic activity by inhibition of proliferation, induction of apoptosis, and 
inhibition of migration and angiogenesis. 
2.2.1. Cancer Chemo-Preventive Effect 
XN shows anti mutagenic activity against mutations induced by the food borne mutagen 2-amino-3-
methylimidazo[4,5-f]quinoline (IQ) [42,43]. Using the Salmonella/microsomal assay system and human 
hepatoma HepG2 cells, XN prevents IQ induced DNA damage [42]. The mechanisms are possibly 
related to the inhibition of the metabolic activation of IQ by human cytochrome P450 1A2 (CYP1A2) 
and the binding of IQ metabolites to DNA and proteins [43]. Besides the protection against IQ induced 
genotoxicity, XN also protects DNA against benzo(a)pyrene (BaP)-induced oxidative stress and DNA 
damage in HepG2 cells [39], and in fresh liver tissue [44]. In HepG2 cells, XN results in significantly 
reduced tert-butyl hydroperoxide (an inducer of reactive oxygen species)-induced DNA strand breaks, 
indicating that its protective effect is mediated by induction of cellular defense mechanisms against 
oxidative stress [39]. Another study revealed that XN significantly reduces menadione induced DNA 
single-strand breaks in Hepa1c1c7 cell and shows good chemo-preventive activity through induction of 
quinone reductase [45,46]. The mechanism by which XN induces quinone reductase is through 
alkylation on kelch-like ECH-associated protein 1 (Keap1). Keap1 sequesters nuclear factor E2-related 
factor 2 (Nrf2) in the cytoplasm, which regulates the expression of the quinone reductase [46].  
The anti-carcinogenic properties at the initiation, promotion, and progression stage of carcinogenesis 
have been investigated and the results showed that XN is a potent chemo-preventive agent [47]. 
Although the mechanism of the protective effect of XN is not yet fully elucidated, the accumulated 
results indicate that XN exhibits anti-genotoxic effects against many mutagens and provide evidence for 
its cancer preventative potential. 
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2.2.2. Anti-Angiogenic Activity 
New vascularization is necessary for tumor growth and metastatic dissemination. Thus, the inhibition 
of tumor angiogenesis is a promising strategy in cancer therapy and prevention. One of the main 
mechanisms of its anticancer activity, XN targets the endothelial and vascular cells, and shows inhibitory 
activities in tumor angiogenesis [48–51]. 
XN administrated to mice in their drinking water inhibits the growth of a vascular tumor in vivo via 
tumor angiogenesis inhibition [48]. Subcutaneous application of XN (l mg/g body weight) for 14 days 
to SCID mice bearing human MX-1 breast tumor xenografts significantly reduces the tumor-induced 
neovascularization by 30% [50]. The mechanisms for its inhibition of angiogenesis are related to the 
blockage of both the nuclear factor-κB (NFκB) and Akt pathways in endothelial cells [48]. XN interferes 
with several points in the angiogenic process, including inhibition of endothelial cell invasion and 
migration, growth, and formation of tubular-like structures in HUVEC cells and HMEC-1 cells [48,50]. 
The identical activity was observed also in human fetal aortic smooth muscle cells [49,51]. However, 
XN exhibits the opposite effect when HUVEC were co-cultured with human fetal aortic smooth muscle 
cells, leading to an increase in the number of cord structures, and showing no inhibitory effects in mature 
vasculature, indicating that XN mainly target the angiogenic, but not the stable vessels [49]. Moreover, 
besides the direct effect on the vascular cells, XN inhibits the production of angiogenic factors in 
pancreatic carcinoma cells and blocks the pancreatic cancer associated angiogenesis, e.g., vascular 
endothelial growth factor (VEGF) and interleukin 8 (IL-8). The inhibition of the angiogenic factors 
production is considered to be via the inhibition of NFκB [52]. 
In addition to the potential use in tumor angiogenesis, the potent anti-angiogenic activity of XN 
indicates that XN may be useful for the treatment of other angiogenesis-related diseases, such as 
endometriosis [53], and wound healing [24,54]. 
2.2.3. Proapoptosis Activity and Modulation of Autophagy 
Generally, both apoptosis and autophagy are tumor suppressor pathways. Apoptosis prevents the 
survival of cancer cells, while autophagy facilitates the degradation of oncogenic molecules, and 
therefore prevents the development of cancers. However, under stress conditions, autophagy also 
facilitates the survival of tumor cells [55]. Consequently, drug-induced apoptosis or modulation of 
autophagy can be effective strategies for treatment of cancer. 
Many researchers have shown that XN exerts anticancer activities by inhibiting proliferation and 
inducing apoptosis of cancer cells. XN induces apoptosis of multiple kinds of cancer cells, including 
human prostate cancer [56,57], leukemia [58,59], ovarian cancer [60], hepatocellular carcinoma [61,62], 
breast carcinoma [63] and human malignant glioblastoma [64,65]. For example, XN showed strong 
anticancer activity against breast cancer MCF-7 and prostate cancer HT-29 cell lines and the inhibitions 
are stronger than the positive control cisplatin [66]. The flavonoid skeleton type and modification of the 
prenyl group may affect the anticancer activity, but it differs in different cell lines [66], indicating that 
multiple mechanisms or targets are involved. The XN induced apoptosis is mainly related to the up 
regulation of anti-apoptotic proteins [67], down regulation of pro-apoptotic proteins, and activation of 
procaspases [68], and it seems that both the death receptor and mitochondrial apoptosis pathway are 
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activated by XN [69]. Oxidative stress response [64,70,71] and endoplasmic reticulum stress response [72] 
are also reported to be involved in the XN induced apoptosis. Additionally, the phosphorylation of 
extracellular-signal-regulated kinase 1/2 (ERK1/2) and rapidly accelerated fibrosarcoma-1 (Raf-1) 
pathway can also be activated by XN in medullary thyroid cancer cells [73]. XN has been shown to 
induce apoptosis by inhibiting NFκB activation [74]. Other mechanisms are also involved in the XN 
induced apoptosis. For example, inhibition of topoisomerase I [75] and aromatase activities [76], as well 
as the decrease in the production of nitric oxide [77]. 
XN may also be a potent chemo- and radio-therapy sensitizer leading to apoptosis. XN sensitizes 
MCF-7/ADR cells to radiation treatment [78]. When treated with XN, multi-drug resistance 1 (MDR1), 
epidermal growth factor receptor (EGFR), and signal transducer and activator of transcription 3 (STAT3) 
decreases in MCF-7/ADR cells, while the death receptor (DR)-4 and DR-5 expression increases [78]. 
XN markedly augments the anticancer activity of tumor necrosis factor related apoptosis-inducing ligand 
(TRAIL) and sensitize TRAIL-resistant cancer cells by engaging extrinsic apoptotic pathway, with increased 
expression of DR-5 receptor in HeLa cells [79], and LNCaP prostate cancer cells [80]. XN, together with 
IX, 6PN, and 8PN, is inhibitor of the efflux transporter breast cancer resistance protein (BCRP/ABCG2), 
indicating its importance for xenobiotic bioavailability and multidrug resistance [81]. However, to the 
best of our knowledge, there is no report about the in vivo inhibition and delay of tumor growth. 
In addition to the potential therapy on solid tumors, XN has an obvious inhibitory effect on the  
non-solid tumors, such as leukemia [82]. XN kills B-chronic lymphocytic leukemia cells by apoptosis [82]. 
XN induces apoptosis in K562 chronic myeloid cells via elevation of intracellular reactive oxygen 
species (ROS). XN inhibits Bcr-Abl expression at both mRNA and protein levels [58]. Furthermore, XN 
induced apoptosis in leukemic cells is related to the inhibition of NFκB, via modification of cysteine 
residues of the IκBα kinase and NFκB by XN [59]. Administration of 50 mg·XN/mouse (5 days/week) 
significantly increased animal life span by delaying the insurgence of neurological disorders due to 
leukemic cell dissemination [83]. Therefore, XN represents a promising agent for leukemia therapy, 
although clinical testing is needed in the near future. 
Autophagy is a bulk, nonspecific protein degradation pathway that is involved in the pathogenesis of 
cancer and neurodegenerative disease. Recent research indicated that XN impairs autophagosome 
maturation of human epidermoid carcinoma A431 cells. The mechanism involves XN binding directly 
to the N-domain of valosin-containing protein (VCP), and acts as a VCP inhibitor. VCP is an essential 
protein for autophagosome maturation [84]. The modulation of autophagy by XN possibly contributes 
to the mechanisms underlying the anticancer activity of XN, although further studies are needed to 
illustrate whether this autophagy inhibit or facilitate the XN induced apoptosis. 
2.2.4. Anti-Invasion Activities 
Metastasis, a characteristic of highly malignant cancers with poor clinical success has been one of the 
major causes for the increased mortality rate in cancer patients. Therefore, the inhibition of cancer cell 
invasion is very important for effective therapies against cancer. 
XN is able to inhibit the invasion of human breast carcinoma MCF-7/6 cells in the chick heart invasion 
assay and of T47-D cells in the collagen invasion assay [85]. The mechanism of the anti-invasive effect 
of XN is related to the up regulation of E-cadherin/catenin invasion suppressor complex [85]. Prostaglandin 
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E2 (PGE2) actuates several pathways implicated in chronic inflammation-related cancer. XN has potential 
to suppress the migration ability of cholangiocarcinoma cell lines by inhibiting PGE2 production [86]. 
Matrix metalloproteinases (MMPs) have been strongly implicated in multiple stages of cancer progression, 
including the acquisition of invasive and metastatic properties. XN shows strong inhibition on the invasive 
phenotype in estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 
negative breast cancers cells, via down regulation of MMP-2 and/or MMP-9 [67]. Cysteine X Cysteine 
(CXC) chemokine receptor 4 (CXCR4) is overexpressed in various tumors and mediates homing of 
tumor cells to distant sites expressing its cognate ligand, CXCL12. XN suppresses CXCR4 expression 
in cancer cells at the transcriptional level via blocking endogenous activation of NFκB, which regulates 
the expression of CXCR4 in cancer cells. Consequently, XN abolishes cell invasion induced by CXCL12 
in both breast and colon cancer cells [87]. Moreover, XN inhibits circular chemorepellent-induced defect 
formation in lymphendothelial cell monolayers, by inhibiting the activity of cytochrome P450, selectin 
E, NFκB, and the expression of intercellular adhesion molecule 1 (ICAM-1) [88]. XN decreases the 
adhesion of tumor cells to endothelial cells, via inhibiting the markers of epithelial-to-mesenchymal 
transition and of cell mobility such as paxillin, myosin light chain 2, and S100A4 in breast cancer  
cells [88]. XN also inhibits leukemia cell invasion, metalloprotease production, and adhesion to 
endothelial cells [58], and therefore also has potential to preventing in vivo life-threatening 
complications of leukostasis and tissue infiltration by leukemic cells. The potential activity against both 
migration and invasion indicates a possible role of XN as an anti-invasive agent in vivo as well. 
2.3. Anti-Inflammatory Activity 
Nitric oxide (NO) plays an important role in many inflammatory responses and is also involved in 
carcinogenesis. In mouse macrophage RAW264.7 cells, XN (10 μg/mL) inhibits more than 90% of the 
NO production by suppressing inducible NO synthase (iNOS) induced by a combination of 
lipopolysaccharide (LPS) and interferon-γ (IFN-γ) [77]. 
Further studies on the anti-inflammatory activity of XN showed that different signaling pathways are 
involved in macrophages. For example, when treated with LPS, XN reduces the expression of the LPS 
receptor components such as Toll-like receptor-4 (TLR4) and myeloid differentiation protein 2 (MD2) 
and results in the suppression of NFκB activation [89,90]; while in the IFN-γ stimulated RAW264.7 
cells, XN inhibits the binding activity of STAT-1α and interferon regulatory factor-1 [89]. 
Excess levels of IL-12 in immune responses such as inflammation or autoimmunity have raised 
considerable interest in IL-12 blocking agents. XN inhibits IL-12 production in stimulated macrophages 
through the down regulation of NFκB [91]. The in vivo anti-inflammatory effect of XN using an 
oxazolone-induced chronic dermatitis model in mouse ear was evaluated, and the results showed that 
dermatitis is attenuated by XN, indicating the potential application of XN in the treatment of skin 
inflammation [91]. 
Cytokine IL-2 plays an important role in the acquired immune responses via T cells. In phorbol  
12-myristate 13-acetate (PMA) and ionomycin activated EL-4 T cells, XN treatment induces a 
significant increase of the IL-2 production at the transcriptional level. Enhanced activity of the IL-2 
promoter, and the up regulation of several transcription factors modulating of IL-2 expression, such as 
nuclear factor of activated T cells (NF-AT) and activator protein-1(AP-1), contributes to the increase of 
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the IL-2 production [92]. Another study showed that XN has profound immunosuppressive effects via 
modulating the T cell mediated response [93]. This suppression of T cell-mediated immune responses 
by XN includes T cell proliferation, development of IL-2 activated killer cells, cytotoxic T lymphocytes, 
and production of Th1 cytokines (IL-2, IFN-γ, and TNF-α). The immunosuppressive effects are possibly 
due to the inhibition of NFκB through suppression of phosphorylation of IκBα [93]. 
XN also reduces the release of several inflammatory factors, such as monocyte chemo attractant 
protein-1 (which plays a crucial role in the inflammatory response) and tumor necrosis factor-γ (TNF-γ) 
in LPS-stimulated RAW 264.7 mouse macrophages and U937 human monocytes [94]. Besides XN, 
other plant-derived polyphenols, e.g., mangostin and kaempferol, can also down regulate TNF and other 
proinflammatory biomarkers [95]. 
XN inhibits LPS-stimulated inflammatory responses in microglial BV2 cells via the Nrf2 pathway 
and upregulates the antioxidant enzymes, NQO1 and HO-1. XN regulates Nrf2 signaling and indicates 
its potential use in the prevention of neurodegenerative diseases associated with inflammation [96]. 
In addition to the regulation of inflammatory factors, XN also shows direct effect on immune cells. 
Dendritic cells (DCs) are key players in the regulation of innate and adaptive immunity. XN induces 
apoptosis of bone marrow-derived DCs via acid sphingomyelinase stimulation and caspase activation [97]. 
The multiple targets and mechanisms of XN may explain its broad anti-inflammatory effects. The 
broad spectrum of anti-inflammatory activity in vitro indicates its potential in treating various diseases 
associated with inflammation. As inflammation has a close relationship with cancer, it is speculated that 
its anti-inflammatory activity may be also one of the possible mechanisms for its anticancer activity. 
However, most of the studies so far are at the in vitro level, and more in vivo studies are needed to 
confirm the anti-inflammatory efficacy. 
2.4. Central Nervous Systems Modulation Properties 
β-Site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) mediates cleavage of β-APP 
and facilitates learning, memory, and synaptic plasticity. It has been proven that BACE1 is a potential 
target for Alzheimer’s disease. BACE1 activities are significantly inhibited by XN with an IC50 value of 
7.19 μM [98]. Therefore, XN may be a potent preventive and therapeutic candidate for Alzheimer’s 
disease [98]. XN exerts neuro protective effects on cerebral ischemic damage in rats. XN results in 
reduction of the infarct volume and the improvement of neuro behavior in cerebral ischemic rats.  
The mechanism is probably related to its inhibition of inflammatory responses (i.e., increase of  
hypoxia-inducible factor-1α, (HIF-1α), iNOS expression, and free radical formation), apoptosis  
(i.e., TNF-α, active caspase-3), and platelet activation [99], indicating its therapeutic potential for 
treatment or prevention of ischemia-reperfusion injury-related disorders. Further investigations showed 
that derivatives of XN can induce neurite growth in mouse neuronal cells [100]. XN has sedative effects 
due to binding to GABAA receptors and hindering the lateral mobility in neurons [101], and this may 
explain why hops are traditionally useful in treating sleeplessness and nervousness. However, other 
compounds in hops can also be at play [1]. Furthermore, in an evaluation of the anxiolytic effects of XN 
using the Sprague-Dawley rat model, the results showed that modulation of the GABAA receptor does 
not contribute to the anxiolysis produced by XN [102]. XN possibly influences other neurotransmitter 
sites in the central nervous system [102]. In the brain of female senescence accelerated mouse, XN 
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improved pro-survival signals and reduces pro-death signals in age-related impairments of neural 
processes [103]. Dietary intake of XN was shown to improve cognitive flexibility in young mice and to 
lower plasma palmitate in young and old mice [104]. Generally, the higher level of protein 
palmitoylation is considered to be associated with poorer learning scores. 
These combined results show that XN has beneficial effects in the central nervous system. However, 
the number of clinical studies supporting the use of XN as a central nervous systems modulator is rather 
limited and the effect of XN at the central nervous system requires a thorough reinvestigation. 
2.5. Antimicrobial Activity 
The discovery of novel antimicrobial agents has been going on for many years. However, the new 
drugs have not kept pace with the increasing drug resistance. One of the major challenges is the limitation 
of screening libraries. Natural plant products, such as chalcones, may contribute to the improvement of 
these chemical libraries. 
XN inhibits human immunodeficiency virus (HIV-1) induced cytopathic effects, the production of 
viral p24 antigen and reverse transcriptase in C8166 lymphocytes [105]. XN also moderately inhibits 
HIV-1 replication in peripheral blood mononuclear cells with an EC50 value of 20.74 µg/mL, but does 
not inhibit the activity of recombinant HIV-1 reverse transcriptase and HIV-1 entry [105]. The results 
suggest that XN is effective against HIV-1 and may serve as an interesting lead compound for 
development of anti-HIV agents. Besides HIV, XN also inhibits the bovine viral diarrhea virus (BVDV), 
the herpes viruses (HSV-1, HSV-2 and CMV) with a low-to-moderate extent [106], and inhibits the 
hepatitis C virus (HCV) replication in cell culture systems, comparable to IFN-α [107]. 
Studies showed that XN displays a broad spectrum of anti-infective activities against bacteria such as 
Staphylococcus aureus [108] and Streptococcus mutans [109]. A recent study has shown that XN inhibits 
the growth of Staphylococcus aureus strains with a MIC range of 15.6–62.5 µg/mL and shows potent 
anti-adherent and anti-biofilm activity [110]. XN also shows anti-fungal activity as evidenced by the 
inhibition of two Trichophyton spp. [111]. 
The broad spectrum of antimicrobial activity of XN has been documented and reviewed [111], 
including the inhibition towards virus, bacteria, and fungi, but the detailed mechanisms of these antimicrobial 
inhibitory activities are still under investigation. Although it has a broad spectrum of antimicrobial 
activity, XN does not affect the composition of intestinal microbiota in rats [112], suggesting an 
unchanged profile for intestinal microbiota when XN is administrated in vivo. 
2.6. Anti-Parasite Effects 
Anti-coccidial effects of XN have been reported and the results showed that XN can reduce the 
invasion by Eimeria tenella sporozoites (SZ) in Madin-Darby bovine kidney cells and reduce the 
invasion by E. tenella and E. acervulina SZ in a chick host. This inhibition is associated with the 
disruption of the apical ends of the SZ [113]. XN results in significantly reduced gross-lesion scores and 
normal chick-host weight gains compared with untreated SZ, indicating XN could be used as anti-coccidial 
feed additive [113]. Moreover, XN and its chalcone derivatives inhibit the in vitro replication of 
Plasmodium falciparum, the major parasite causing malaria. The anti-plasmodial mechanisms may be 
related to interference with the glutathione-dependent haemin-degradation process of P. falciparum [114]. 
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2.7. Effect on Bone Disease 
Bone remodeling is a dynamic process which is maintained by a balance between bone formation and 
bone resorption. XN has a strong inhibitory effect on bone resorption, and is speculated as a precursor 
of phytoestrogen compounds because the demethylxanthohumol is a proestrogen and is metabolized to 
the active estrogenic compound prenylnaringenin in vivo [115]. XN dose-dependently stimulates osteogenic 
marker gene (Runx2, ALPL, and BGLAP) expression as well as ALPL activity in murine mesenchymal and 
pre-osteoblast cell lines, reciprocally affecting the osteogenic versus the adipogenic differentiation 
pathway [116]. However, XN does not show progestogenic or androgenic bioactivity, and the endocrine 
properties of hops and hop products are due to the estrogenic activity of 8PN [117]. Receptor activator 
NFκB ligand (RANKL) has been shown to play a critical role in osteoclast formation and bone 
resorption. The newest research showed that XN markedly inhibits RANKL-induced tartrate-resistant 
acid phosphatase activity, multinucleated osteoclasts formation, resorption-pit formation, and modulates 
the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells [118]. These 
results indicate that XN inhibits osteoclastogenesis and may be useful for the prevention of bone diseases. 
An early reaction in osteoarthritic chondrocytes is hyaluronan overproduction followed by proteoglycan 
loss and collagen degradation. XN inhibits hyaluronan export [119,120], as well as proteoglycan and 
collagen loss, and prevents the shedding of metalloproteases into the culture medium [119]. The 
mechanism is that XN directly binds and inhibits the hyaluronan exporting protein, multidrug resistance 
associated protein 5 (MRP5) [119,121], while not influencing the hyaluronan synthase activity [119]. 
Therefore, XN may be a natural compound to prevent hyaluronan overproduction and subsequent 
reactions in osteoarthritis. 
2.8. Hepatic Protection 
2.8.1. Protection in Chemical Hepatic Injury 
XN has the potential as functional nutrient for prevention or treatment of non-alcoholic 
steatohepatitis. Hepatocytes and hepatic stellate cells (HSC) are central mediators of liver fibrogenesis. 
XN inhibits the activation of primary human HSC and induces apoptosis in activated HSC in vitro 
without impairing viability of primary human hepatocytes. XN inhibits the activation of NFκB and the 
expression of NFκB dependent pro-inflammatory genes [122]. In vivo, feeding of XN reduces hepatic 
inflammation and inhibits the expression of profibrogenic genes in a murine model of non-alcoholic 
steatohepatitis [122]. In addition, in a liver injury rat model induced by carbon tetrachloride  
(CCl4) [123,124] and in a hepatocyte model induced by tert-butyl hydroperoxide (TBH) [125], XN 
shows obvious protective effects against toxic liver injury. The mechanisms are related to the inhibition 
of hepatic inflammation via decreasing NFκB activity [123], inhibition of lipid peroxidation [124,125], 
and protection against the degradation of antioxidant enzymes [124]. XN induces the detoxification 
enzyme, NAD(P)H-quinone oxidoreductase (NQO1) in vitro and in the liver [126], by modifying Keap1, 
which induces Nrf2 translocation and antioxidant response element activation [126]. The mechanisms 
are similar to that in the cancer chemo-preventive and anti-inflammation effect, as are result of Keap1 
alkylation and the resulting activation of antioxidant enzymes are also involved [46,96]. XN acts as a 
protective agent against oxidative damage induced in rat liver and other tissues after acute intoxication 
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due to ethanol administration [127]. In normal hepatocytes, the chemopreventive activity of XN may 
relate to the activation of Nrf2, phase II enzymes, and induction of p53 [61]. These studies further 
indicate the potential application treatment of liver fibrosis in response to hepatic injury. 
2.8.2. Protection in Liver Ischemia/Reperfusion Injur 
Liver ischemia/reperfusion (I/R) leads to the formation of ROS, causing hepatic injury and initiating 
an inflammatory response, which is a critical problem after liver surgery and transplantation. In a mouse 
model of warm I/R liver injury, I/R-induced oxidative stress was significantly inhibited by XN. The 
mechanism is related to the inhibition of AKT, NFκB, and the proinflammatory genes [40]. However, 
in a cold I/R model, XN does not protect against I/R injury in rat liver [128]. The reason for the 
conflicting observations is possibly due to the different models, experimental conditions, and the XN 
concentration in the experiments [40]. 
2.8.3. Benefits in Liver Diseases Associated with Virus Infection 
HCV infection is a one of the major causes of liver infectious diseases. In vitro studies using BVDV, 
a model of HCV, showed that XN inhibits BVDV replication and enhanced the anti-viral activity of  
IFN-α [129,130]. In in vivo HCV infected Tupaias, XN reduces hepatic inflammation, steatosis, and 
fibrosis. The mechanisms are related to the inhibition of oxidative reaction, regulation of apoptosis, 
modulation of microsomal triglyceride transfer protein activity, and inhibition of hematopoietic stem 
cells [131]. 
2.9. Effects on Skin Disease 
A study of XN on melanogenesis using B16 melanoma cells showed that XN might act as a  
hypo-pigmenting agent through the down regulation of microphthalmia-associated transcription factor 
(MITF) in the cAMP-dependent melanogenic pathway [132]. XN inhibits against collagenase activities 
(MMP-1 and MMP-8) and attenuates the oxidative damage to the skin, which are beneficial to the 
pathogenesis of acne vulgaris [108]. XN improves skin structure and firmness, mainly through inhibition 
of the elastase activity and MMPs and stimulating the biosynthesis of fibrillar collagens, elastin, and 
fibrillins [133]. Therefore, XN has potential as an anti-skin-aging agent. More physiological effects on 
skin health of XN and other beer compounds have been reviewed recently [134]. Potential uses of these 
substances in dermatology may include treatment of atopic eczema, contact dermatitis, pigment 
disorders, skin infections, skin ageing, skin cancers, and photo protection. 
2.10. Thyroid Diseases 
Sodium-iodide-symporter, an integral plasma membrane glycoprotein, mediates the sodium-dependent 
active uptake of iodide into the thyroid gland, which is a fundamental step in thyroid hormone synthesis. 
Recent reults have shown that nanomolar concentrations of XN stimulates the uptake of iodide in rat 
thyrocyte cells. Therefore, XN may be an interesting candidate for more efficient radioiodide therapy of 
the thyroid [135]. In additon, XN has an effect on certain drug transporters and modulates the transport 
of several drugs [136–138]. XN also affects the thyroid hormone distribution and metabolism by 
Molecules 2015, 20 766 
 
 
modulation hepatic expression of sulfotransferase, uridine-diphosphate glucuronosyltransferase, and the 
constitutive androstane receptor [139]. 
2.11. Benefits in the Thromboembolic Disease 
Blood platelet activation and aggregation contributes to the atherothrombotic events. Studies showed 
that XN possesses potent antiplatelet activity via inhibition of the PI3-kinase/Akt, p38 MAPK, and 
PLCγ2-PKC pathways, and the inhibition on thromboxane A2 formation and [Ca2+]i [140]. XN inhibits 
suicidal erythrocyte death induced by oxidative stress and energy depletion in vitro. Since eryptotic cells 
are cleared from the circulating blood and impede microcirculation, this novel effect of XN may be used 
in the prevention or treatment of anemia and disorders of microcirculation and coagulation [141]. 
Therefore, XN has potential in the treatment of thromboembolic disorders. 
2.12. Pharmacokinetics and Biotransformation of XN 
In rat and human liver microsomes, XN can be biotransformed to glucuronides and hydroxylated 
metabolies and cyclic dehydro-metabolites [142,143]. Investigations using human liver microsomes 
showed that hydroxylation of a prenyl methyl group is the primary route of the oxidative metabolism, 
forming hydroxylated metabolites of XN and IX. IX may be O-demethylated by human hepatic 
cytochromes P450 or gut microbial enzymes to form 8PN (Scheme 1). An important possibility is that 
XN may be converted into IX in the stomach which again may be converted to 8PN. Some of the effects 
of XN may therefore in effect be caused by 8PN [144,145]. XN can also undergo direct metabolic 
conversion to desmethylxanthohumol (DMX), which is later converted into either 6-prenylnaringenin 
(6PN) or into 8PN [146]. Both 6PN and 8PN are strong phytoestrogens. Studies in menopausal women 
to evaluate safety and pharmacokinetics of extract of hops also confirmed demethylation of IX to form 
8PN and cyclization of XN to IX [147].When XN is fed to rats in a dose of 1000 mg·kg−1 body weight, 
feces is the major route of excretion [148,149]. 22 metabolites are identified in the feces, most of them 
confined to modified chalcone structures and flavanone derivatives [150]. However, indicating most of 
the XN remains unchanged in the intestinal tract of as approximately 89% is XN and only 11% is 
metabolites [150]. Phase II metabolites of XN in rats are also identified revealing oxidation, 
demethylation, hydration and sulfatation reactions [151]. Due to the multiple biotransformation of XN, 
we should keep in mind that, some of the metabolites of XN may contribute to the biological activity of 
XN, such as the estrogenic activity of 8PN and 6PN, and the products of biotransformation of XN, 
together with other prenylated hop flavonoids, could serve as an inspiration for drug design [66]. 
The pharmacokinetics of XN both in rats and in humans have been studied and provide 
pharmacokinetics parameters for XN [146,152]. The bioavailability of XN is dose-dependent and 
approximately 0.33, 0.13, and 0.11 in rats, when single orally administrated 1.86, 5.64, and 16.9 mg/kg 
body weight [152]. Human pharmacokinetics results showed that, following oral administration, XN 
shows a linear response with increasing oral dose, and XN has a distinct biphasic absorption pattern. XN 
and IX conjugates are the major circulating metabolites [146]. Slow absorption after oral administration 
in human and enterohepatic recirculation contributes to long half-lives of XN [147]. The collected data 
from rats and human demonstrate that there is similarity in XN metabolism between animals and 
humans, allowing for translation of animal study findings to future clinical studies. 




Scheme 1. Pathway for XN metabolism and production of its metabolites: IX, 6PN, 8PN, 
and DMX. Reproduced from reference [152]. 
Due to its low bioavailability in the human organism, much work has been performed to investigate 
the actual concentrations and pharmacokinetics in liver and intestinal cells. XN can accumulate rapidly 
in intestinal cells and most of the XN molecules are bound to cellular proteins. About 70% of XN in the 
apical side of Caco-2 cells accumulates inside the cells, and 93% of the intracellular XN is localized in 
the cytosol, and facilitated transport is not involved in the uptake of XN [153,154]. This specific binding 
of XN to cytosolic proteins in intestinal epithelial cells may contribute to the poor oral bioavailability  
in vivo [154]. Studies have also been done to investigate the interaction of XN with phosphatidylcholine 
model membranes [155,156], using X-ray diffraction, Fourier transform infrared spectroscopy, 
differential scanning calorimetry, and fluorescence spectroscopy. The results showed that XN inserts 
into lipid bilayers and affects molecular organization and biophysical properties of the bilayer [155,156], 
and this interaction may contribute to the rapid transport through the cell membrane. 
2.13. Safety of XN 
Toxicological studies in animals revealed that XN possesses good tolerance. The oral administration 
of XN (5 × 10−4 M ad libitum) to mice for 4 weeks did not affect the major organ functions, nor the 
protein, lipid, and carbohydrate metabolism [157]. Similarly, female BALB/c mice fed on XN  
(1000 mg/kg body weight) for 3 weeks exhibit no adverse effects on major organ function and 
homoeostasis [158]. Another study reported subchronic 4-week toxicity as well as its influence on 
fertility and development of offspring [159]. Sprague Dawley rats were treated with 0.5% XN in the diet 
or with 1000 mg/kg body weight per day by gavage for 28 days. Weak hepatotoxicity and poor 
development of mammary glands are observed in rats [159]. Furthermore, administration with XN  
(100 mg/kg body weight per day), does not cause any adverse effects on female reproduction and the 
development of offspring. However, XN treatment of male rats prior to mating significantly increases 
the sex ratio of male to female offspring [159]. An escalating dose study was carried out in menopausal 
women to evaluate safety of hops extract rich in XN, and the results showed this extract does not affect 













































It is only recently that researchers showed an increasing interest in XN and especially its biological 
activities. The anti-inflammatory, antioxidant, hypoglycemic activities, anticancer effects, and so on, 
assessed both in vitro and in vivo studies, strongly suggest a potential prevention and treatment of many 
diseases. The antioxidant activity may contribute to several ROS related diseases by acting directly as 
reducing compound, or indirectly by inducing the cellular defense mechanisms to overcome the oxidant 
stress [38–40]. Some of the molecular targets for their bioactivity are identified, and the interaction 
between XN and the target has also been investigated, including alkylation on the cysteine residues of 
Keap1, IκBα kinase, and NFκB by Michael addition [46,59], as well as binding directly to the VCP [84] 
and MRP5 [121]. It should be noted that Keap 1 is an important target for the bioactivity of XN, such as 
cancer chemo-prevention, hepatic protection, anti-inflammation, because alkylation on Keap1 activates 
antioxidant enzymes, such as quinine reductase, NQO1, HO-1, via the regulations of Nrf2 [46,96,126]. 
In vivo and in vitro studies to assess their bioavailability, distribution, efficacy, and safety in animal 
models and on humans have been performed with promising results for humans. The most important dietary 
source of XN is beer. However, XN is a minor prenylflavonoid in beer due to thermal isomerization of 
chalcones into flavanones during the brewing process [5], and pharmacologically relevant concentrations 
cannot be reached by consumption of regular beer. Now, it is possible not only to isolate XN but also to 
stabilize it in liquids and foodstuff with a high concentration [160] despite its low solubility in water. 
Therefore, pharmacological relevant concentrations can be reached by oral administration of XN enriched 
functional food, e.g. XN enriched beer, tea, fruit juice, solid foods (such as menohop® (Metagenics, San 
Clements, CA, USA). Furthermore, in relation to XN being used as a drug, there is still a lot of work to 
be done in order to develop XN as a reliable drug for specific therapeutic applications in the clinic. 
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